ID,Class of Spike-Binding Protein,Spike-Binding Protein,Chains (If Cocktail),Model Name,Resolution,Title,Released,DOI
6W41,Antibody,CR3022,,6W41_1,3.084,Crystal structure of SARS-CoV-2 receptor binding domain in complex with human antibody CR3022,2020-03-25,10.1126/science.abb7269
6WPS,Antibody,S309,,6WPS_1;6WPS_2;6WPS_3,"3.1, 3.1",Structure of the SARS-CoV-2 spike glycoprotein in complex with the S309 neutralizing antibody Fab fragment,2020-05-27,10.1038/s41586-020-2349-y
6WPT,Antibody,S309,,6WPT_1;6WPT_2,"3.7, 3.7",Structure of the SARS-CoV-2 spike glycoprotein in complex with the S309 neutralizing antibody Fab fragment (open state),2020-05-27,10.1038/s41586-020-2349-y
6XC2,Antibody,CC12.1,,6XC2_1;6XC2_2,3.112,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CC12.1,2020-07-08,10.1126/science.abd2321
6XC3,Antibody,CC12.1,"A,B",6XC3_1,2.698,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CC12.1 and CR3022,2020-07-08,10.1126/science.abd2321
6XC3,Antibody,CR3022,"H,L",6XC3_2,2.698,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CC12.1 and CR3022,2020-07-08,10.1126/science.abd2321
6XC4,Antibody,CC12.3,,6XC4_1;6XC4_2,2.341,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CC12.3,2020-07-08,10.1126/science.abd2321
6XC7,Antibody,CC12.3,"C,D",6XC7_1,2.883,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CC12.3 and CR3022,2020-07-08,10.1126/science.abd2321
6XC7,Antibody,CR3022,"H,L",6XC7_2,2.883,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CC12.3 and CR3022,2020-07-08,10.1126/science.abd2321
6XCM,Antibody,C105,,6XCM_1;6XCM_2,3.42,Structure of the SARS-CoV-2 spike glycoprotein in complex with the C105 neutralizing antibody Fab fragment (state 1),2020-07-01,10.1016/j.cell.2020.06.025
6XCN,Antibody,C105,,6XCN_1;6XCN_2;6XCN_3,3.66,Structure of the SARS-CoV-2 spike glycoprotein in complex with the C105 neutralizing antibody Fab fragment (state 2),2020-07-01,10.1016/j.cell.2020.06.025
6XDG,Antibody,REGN10933,"B,D",6XDG_1,3.9,Complex of SARS-CoV-2 receptor binding domain with the Fab fragments of two neutralizing antibodies,2020-06-24,10.1126/science.abd0827
6XDG,Antibody,REGN10987,"A,C",6XDG_2,3.9,Complex of SARS-CoV-2 receptor binding domain with the Fab fragments of two neutralizing antibodies,2020-06-24,10.1126/science.abd0827
6XE1,Antibody,CV30,,6XE1_1,2.75,"Structure of SARS-CoV-2 spike protein receptor binding domain in complex with a potent neutralizing antibody, CV30 Fab",2020-07-01,10.1101/2020.06.12.148692
6XEY,Antibody,2-4,,6XEY_1;6XEY_2;6XEY_3,3.25,Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-4,2020-07-22,10.1038/s41586-020-2571-7
6XKP,Antibody,CV07-270,,6XKP_1;6XKP_2,2.72,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CV07-270,2020-10-14,10.1016/j.cell.2020.09.049
6XKQ,Antibody,CV07-250,,6XKQ_1,2.55,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CV07-250,2020-10-14,10.1016/j.cell.2020.09.049
6YLA,Antibody,CR3022,,6YLA_1;6YLA_2,2.42,Crystal structure of the SARS-CoV-2 receptor binding domain in complex with CR3022 Fab,2020-04-15,10.1016/j.chom.2020.06.010
6YM0,Antibody,CR3022,,6YM0_1,4.36,Crystal structure of the SARS-CoV-2 receptor binding domain in complex with CR3022 Fab (crystal form 1),2020-04-29,10.1016/j.chom.2020.06.010
6YOR,Antibody,CR3022,,6YOR_1;6YOR_2,"3.3, 3.9",Structure of the SARS-CoV-2 spike S1 protein in complex with CR3022 Fab,2020-04-29,10.1016/j.chom.2020.06.010
6YZ7,Antibody,CR3022,"BBB,CCC,HHH,LLL",,3.3,"H11-D4, SARS-CoV-2 RBD, CR3022 ternary complex",2020-06-03,
6Z2M,Antibody,CR3022,"B,C,H,L",6Z2M_1,2.71,"H11-D4, SARS-CoV-2 RBD, CR3022 ternary complex",2020-06-03,
6ZCZ,Antibody,EY6A,"H,L",,2.65,Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in ternary complex with EY6A Fab and a nanobody.,2020-06-24,10.1038/s41594-020-0480-y
6ZDG,Antibody,EY6A,,6ZDG_1;6ZDG_2;6ZDG_3,4.7,Association of three complexes of largely structurally disordered Spike ectodomain with bound EY6A Fab,2020-07-29,10.1038/s41594-020-0480-y
6ZDH,Antibody,EY6A,,6ZDH_1;6ZDH_2;6ZDH_3,3.7,SARS-CoV-2 Spike glycoprotein in complex with a neutralizing antibody EY6A Fab,2020-07-01,10.1038/s41594-020-0480-y
6ZER,Antibody,EY6A,,6ZER_1;6ZER_2;6ZER_3,3.8,Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with EY6A Fab,2020-06-24,10.1038/s41594-020-0480-y
6ZFO,Antibody,EY6A,,6ZFO_1;6ZFO_2,4.4,Association of two complexes of largely structurally disordered Spike ectodomain with bound EY6A Fab,2020-07-08,10.1038/s41594-020-0480-y
6ZH9,Antibody,CR3022,"HHH,LLL",,3.31,Ternary complex CR3022 H11-H4 and RBD (SARS-CoV-2),2020-09-02,10.1038/s41594-020-0469-6
6ZLR,Antibody,CR3022,,,3.1,Soaking competent crystal form of the SARS-CoV-2 Receptor Binding Domain (RBD):CR3022 complex.,2020-12-23,10.3389/fphar.2020.615211
7A5R,Antibody,CR3022,,7A5R_1;7A5R_2,3.7,Complex of SARS-CoV-2 spike and CR3022 Fab (Non-Uniform Refinement),2020-09-16,10.1038/s41467-020-19146-5
7A5S,Antibody,CR3022,,7A5S_1;7A5S_2,3.9,Complex of SARS-CoV-2 spike and CR3022 Fab (Homogeneous Refinement),2020-09-16,10.1038/s41467-020-19146-5
7AKD,Antibody,47D11,,7AKD_1;7AKD_2,4,Structure of the SARS-CoV-2 spike glycoprotein in complex with the 47D11 neutralizing antibody Fab fragment,2021-05-19,10.1126/sciadv.abf5632
7B3O,Antibody,STE90-C11,,7B3O_1,2,Crystal structure of the SARS-CoV-2 RBD in complex with STE90-C11 Fab,2020-12-16,10.1016/j.celrep.2021.109433
7BEH,Antibody,COVOX-316,,7BEH_1,2.3,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-316 Fab,2021-03-03,10.1016/j.cell.2021.02.032
7BEI,Antibody,COVOX-150,,7BEI_1,2.3,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-150 Fab,2021-03-03,10.1016/j.cell.2021.02.032
7BEJ,Antibody,COVOX-158,,7BEJ_1,2.42,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-158 Fab (crystal form 1),2021-03-03,10.1016/j.cell.2021.02.032
7BEK,Antibody,COVOX-158,,7BEK_1,2.04,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-158 Fab (crystal form 2),2021-03-03,10.1016/j.cell.2021.02.032
7BEL,Antibody,COVOX-45,"A,B,C,D",7BEL_2;7BEL_3,2.53,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-88 and COVOX-45 Fabs,2021-03-03,10.1016/j.cell.2021.02.032
7BEL,Antibody,COVOX-88,"E,F,H,L",7BEL_1;7BEL_4,2.53,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-88 and COVOX-45 Fabs,2021-03-03,10.1016/j.cell.2021.02.032
7BEM,Antibody,COVOX-269,,7BEM_1,2.52,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-269 scFv,2021-03-03,10.1016/j.cell.2021.02.032
7BEN,Antibody,COVOX-253,"D,F,H,L",7BEN_2;7BEN_3,2.5,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-253 and COVOX-75 Fabs,2021-03-03,10.1016/j.cell.2021.02.032
7BEN,Antibody,COVOX-75,"A,B,G,I",7BEN_1;7BEN_4,2.5,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-253 and COVOX-75 Fabs,2021-03-03,10.1016/j.cell.2021.02.032
7BEO,Antibody,COVOX-253H55L,"C,D,H,L",7BEO_1;7BEO_4,3.19,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-253H55L and COVOX-75 Fabs,2021-03-03,10.1016/j.cell.2021.02.032
7BEO,Antibody,COVOX-75,"A,B,E,F",7BEO_2;7BEO_3,3.19,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-253H55L and COVOX-75 Fabs,2021-03-03,10.1016/j.cell.2021.02.032
7BEP,Antibody,COVOX-384,"A,B,D,F",7BEP_2;7BEP_3,2.61,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-384 and S309 Fabs,2021-03-03,10.1016/j.cell.2021.02.032
7BEP,Antibody,S309,"G,I,H,L",7BEP_1;7BEP_4,2.61,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-384 and S309 Fabs,2021-03-03,10.1016/j.cell.2021.02.032
7BNV,Antibody,ION-300,,7BNV_1,2.35,Crystal Structure of the SARS-CoV-2 Receptor Binding Domain in Complex with Antibody ION-300,2021-11-17,10.3389/fimmu.2021.678570
7BWJ,Antibody,P2B-2F6,,7BWJ_1,2.85,crystal structure of SARS-CoV-2 antibody with RBD,2020-06-03,10.1038/s41586-020-2380-z
7BYR,Antibody,BD23,,7BYR_1,3.84,BD23-Fab in complex with the S ectodomain trimer,2020-06-10,10.1016/j.cell.2020.05.025
7BZ5,Antibody,B38,,7BZ5_1,1.84,Structure of COVID-19 virus spike receptor-binding domain complexed with a neutralizing antibody,2020-05-13,10.1126/science.abc2241
7C01,Antibody,CB6,,7C01_1;7C01_2,2.88,Molecular basis for a potent human neutralizing antibody targeting SARS-CoV-2 RBD,2020-05-27,10.1038/s41586-020-2381-y
7C2L,Antibody,4A8,,7C2L_1;7C2L_2;7C2L_3,3.1,S protein of SARS-CoV-2 in complex bound with 4A8,2020-07-01,10.1126/science.abc6952
7CAC,Antibody,H014,,7CAC_1,3.55,SARS-CoV-2 S trimer with one RBD in the open state and complexed with one H014 Fab.,2021-02-24,10.1126/science.abc5881
7CAH,Antibody,H014,,7CAH_1,3.9,The interface of H014 Fab binds to SARS-CoV-2 S,2020-08-12,10.1126/science.abc5881
7CAI,Antibody,H014,,7CAI_1;7CAI_2,3.49,SARS-CoV-2 S trimer with two RBDs in the open state and complexed with two H014 Fab,2020-09-23,10.1126/science.abc5881
7CAK,Antibody,H014,,7CAK_1;7CAK_2;7CAK_3,3.58,SARS-CoV-2 S trimer with three RBD in the open state and complexed with three H014 Fab,2020-09-23,10.1126/science.abc5881
7CDI,Antibody,P2C-1F11,,7CDI_1,2.96,Crystal structure of SARS-CoV-2 antibody P2C-1F11 with RBD,2020-11-18,10.1038/s41467-020-20501-9
7CDJ,Antibody,P2C-1A3,,7CDJ_1,3.396,Crystal structure of SARS-CoV-2 antibody P2C-1A3 with RBD,2020-11-18,10.1038/s41467-020-20501-9
7CH4,Antibody,BD-604,,7CH4_1,3.15,Crystal structure of the SARS-CoV-2 S RBD in complex with BD-604 Fab,2020-09-16,10.1016/j.cell.2020.09.035
7CH5,Antibody,BD-629,,7CH5_1,2.7,Crystal structure of the SARS-CoV-2 S RBD in complex with BD-629 Fab,2020-09-16,10.1016/j.cell.2020.09.035
7CHB,Antibody,BD-236,,7CHB_1,2.4,Crystal structure of the SARS-CoV-2 RBD in complex with BD-236 Fab,2020-09-16,10.1016/j.cell.2020.09.035
7CHC,Antibody,BD-368-2,"A,B",7CHC_2,2.71,Crystal structure of the SARS-CoV-2 S RBD in complex with BD-629 Fab and BD-368-2 Fab,2020-09-16,10.1016/j.cell.2020.09.035
7CHC,Antibody,BD-629,"H,L",7CHC_1,2.71,Crystal structure of the SARS-CoV-2 S RBD in complex with BD-629 Fab and BD-368-2 Fab,2020-09-16,10.1016/j.cell.2020.09.035
7CHE,Antibody,BD-236,"H,L",7CHE_1,3.416,Crystal structure of the SARS-CoV-2 RBD in complex with BD-236 Fab and BD-368-2 Fab,2020-09-16,10.1016/j.cell.2020.09.035
7CHE,Antibody,BD-368-2,"A,B",7CHE_2,3.416,Crystal structure of the SARS-CoV-2 RBD in complex with BD-236 Fab and BD-368-2 Fab,2020-09-16,10.1016/j.cell.2020.09.035
7CHF,Antibody,BD-368-2,"A,B",7CHF_1,2.674,Crystal structure of the SARS-CoV-2 RBD in complex with BD-604 Fab and BD-368-2 Fab,2020-09-16,10.1016/j.cell.2020.09.035
7CHF,Antibody,BD-604,"H,L",7CHF_2,2.674,Crystal structure of the SARS-CoV-2 RBD in complex with BD-604 Fab and BD-368-2 Fab,2020-09-16,10.1016/j.cell.2020.09.035
7CHH,Antibody,BD-368-2,,7CHH_1;7CHH_2;7CHH_3,3.49,Cryo-EM structure of the SARS-CoV-2 S-6P in complex with BD-368-2 Fabs,2020-09-16,10.1016/j.cell.2020.09.035
7CHO,Antibody,P5A-1D2,,7CHO_1;7CHO_2,2.561,Crystal structure of SARS-CoV-2 antibody P5A-1D2 with RBD,2021-05-19,10.1038/s41467-021-24514-w
7CHP,Antibody,P5A-3C8,,7CHP_1,2.357,Crystal structure of SARS-CoV-2 antibody P5A-3C8 with RBD,2021-05-19,10.1038/s41467-021-24514-w
7CHS,Antibody,P22A-1D1,,7CHS_1,2.401,Crystal structure of SARS-CoV-2 antibody P22A-1D1 with RBD,2021-05-19,10.1038/s41467-021-24514-w
7CJF,Antibody,P4A1,,7CJF_1,2.108,Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody Fab,2020-11-11,10.1038/s41467-021-22926-2
7CM4,Antibody,CT-P59,,7CM4_1,2.71,Crystal Structure of COVID-19 virus spike receptor-binding domain complexed with a neutralizing antibody CT-P59,2021-01-20,10.1038/s41467-020-20602-5
7CWL,Antibody,P17,,7CWL_1;7CWL_2;7CWL_3,3.8,SARS-CoV-2 spike protein and P17 fab complex with one RBD in close state,2021-01-27,10.1038/s41422-020-00444-y
7CWM,Antibody,P17,,7CWM_1;7CWM_2;7CWM_3,3.6,Complex of SARS-CoV-2 spike protein and Fab P17 with one RBD in open state and two RBD in closed state,2020-12-16,10.1038/s41422-020-00444-y
7CWN,Antibody,H014,"D,E,M,H,N,O",7CWN_2;7CWN_4;7CWN_5,3.2,P17-H014 Fab cocktail in complex with SARS-CoV-2 spike protein,2020-12-16,10.1038/s41422-020-00444-y
7CWN,Antibody,P17,"F,G,I,K,J,L",7CWN_1;7CWN_3;7CWN_6,3.2,P17-H014 Fab cocktail in complex with SARS-CoV-2 spike protein,2020-12-16,10.1038/s41422-020-00444-y
7CWO,Antibody,P17,,7CWO_1,3.9,SARS-CoV-2 spike protein RBD and P17 fab complex,2020-12-16,10.1038/s41422-020-00444-y
7CWS,Antibody,FC05,"C,L,K,M,N,P",7CWS_1;7CWS_4;7CWS_5,3.4,SARS-CoV-2 Spike Proteins Trimer in Complex with FC05 and H014 Fabs Cocktail,2020-12-16,10.1038/s41422-020-00446-w
7CWS,Antibody,H014,"D,E,F,G,H,I",7CWS_2;7CWS_3;7CWS_6,3.4,SARS-CoV-2 Spike Proteins Trimer in Complex with FC05 and H014 Fabs Cocktail,2020-12-16,10.1038/s41422-020-00446-w
7CWT,Antibody,FC05,"H,K,L,M,N,P",7CWT_1;7CWT_3;7CWT_6,3.7,SARS-CoV-2 Spike protein in complex with hb27 and fc05 Fab cocktail,2021-06-23,10.1038/s41422-020-00446-w
7CWT,Antibody,HB27,"D,E,F,G,I,J",7CWT_2;7CWT_4;7CWT_5,3.7,SARS-CoV-2 Spike protein in complex with hb27 and fc05 Fab cocktail,2021-06-23,10.1038/s41422-020-00446-w
7CWU,Antibody,FC05,"F,G,I,J,N,P",7CWU_1;7CWU_3;7CWU_5,3.5,SARS-CoV-2 spike proteins trimer in complex with P17 and FC05 Fabs cocktail,2020-12-16,10.1038/s41422-020-00446-w
7CWU,Antibody,P17,"H,L,M,O,R,S",7CWU_2;7CWU_4;7CWU_6,3.5,SARS-CoV-2 spike proteins trimer in complex with P17 and FC05 Fabs cocktail,2020-12-16,10.1038/s41422-020-00446-w
7CYH,Antibody,HB27,,7CYH_1,3.9,Binding interface of SARS-CoV-2 RBD and its neutralizing antibody HB27,2021-06-09,
7CYP,Antibody,HB27,,7CYP_1;7CYP_2;7CYP_3,3.5,Complex of SARS-CoV-2 spike trimer with its neutralizing antibody HB27,2021-06-09,
7CYV,Antibody,FD20,,7CYV_1,3.13,"Crystal structure of FD20, a neutralizing single-chain variable fragment (scFv) in complex with SARS-CoV-2 Spike receptor-binding domain (RBD)",2021-09-15,
7CZP,Antibody,P2B-1A1,,7CZP_1;7CZP_2,3,S protein of SARS-CoV-2 in complex bound with P2B-1A1,2021-03-10,10.1038/s41422-021-00487-9
7CZQ,Antibody,P2B-1A10,,7CZQ_1;7CZQ_2,2.8,S protein of SARS-CoV-2 in complex bound with P2B-1A10,2021-03-10,10.1038/s41422-021-00487-9
7CZR,Antibody,P5A-1B8_2B,,7CZR_1;7CZR_2,3.5,S protein of SARS-CoV-2 in complex bound with P5A-1B8_2B,2021-03-10,10.1038/s41422-021-00487-9
7CZS,Antibody,P5A-1B8_3B,,7CZS_1;7CZS_2;7CZS_3,3.6,S protein of SARS-CoV-2 in complex bound with P5A-1B8_3B,2021-03-10,10.1038/s41422-021-00487-9
7CZT,Antibody,P5A-2G9,,7CZT_1;7CZT_2,2.7,S protein of SARS-CoV-2 in complex bound with P5A-2G9,2021-03-10,10.1038/s41422-021-00487-9
7CZU,Antibody,P5A-1B6_2B,,7CZU_1;7CZU_2,3.4,S protein of SARS-CoV-2 in complex bound with P5A-1B6_2B,2021-03-10,10.1038/s41422-021-00487-9
7CZV,Antibody,P5A-1B6_3B,,7CZV_1;7CZV_2;7CZV_3,3.3,S protein of SARS-CoV-2 in complex bound with P5A-1B6_3B,2021-03-10,10.1038/s41422-021-00487-9
7CZW,Antibody,P5A-2G7,,7CZW_1;7CZW_2,2.8,S protein of SARS-CoV-2 in complex bound with P5A-2G7,2021-03-10,10.1038/s41422-021-00487-9
7CZX,Antibody,P5A-1B9,,7CZX_1;7CZX_2;7CZX_3,2.8,S protein of SARS-CoV-2 in complex bound with P5A-1B9,2021-03-10,10.1038/s41422-021-00487-9
7CZY,Antibody,P5A-2F11_2B,,7CZY_1;7CZY_2,3.3,S protein of SARS-CoV-2 in complex bound with P5A-2F11_2B,2021-03-10,10.1038/s41422-021-00487-9
7CZZ,Antibody,P5A-2F11_3B,,7CZZ_1;7CZZ_2;7CZZ_3,3.2,S protein of SARS-CoV-2 in complex bound with P5A-2F11_3B,2021-03-10,10.1038/s41422-021-00487-9
7D00,Antibody,FabP5A-1B8,,7D00_1;7D00_2,3,S protein of SARS-CoV-2 in complex bound with FabP5A-1B8,2021-03-10,10.1038/s41422-021-00487-9
7D03,Antibody,FabP5A-2G7,,7D03_1,3.2,S protein of SARS-CoV-2 in complex bound with FabP5A-2G7,2021-03-10,10.1038/s41422-021-00487-9
7D0B,Antibody,P5A-3C12_1B,,7D0B_1,3.9,S protein of SARS-CoV-2 in complex bound with P5A-3C12_1B,2021-03-10,10.1038/s41422-021-00487-9
7D0C,Antibody,P5A-3A1,,7D0C_1;7D0C_2,3.4,S protein of SARS-CoV-2 in complex bound with P5A-3A1,2021-03-10,10.1038/s41422-021-00487-9
7D0D,Antibody,P5A-3C12_2B,,7D0D_1;7D0D_2,3.8,S protein of SARS-CoV-2 in complex bound with P5A-3C12_2B,2021-03-10,10.1038/s41422-021-00487-9
7D4G,Antibody,FC05,,7D4G_1,3.9,A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2,2021-04-07,
7D6I,Antibody,GH12,,7D6I_1,3.41,A neutralizing MAb targeting receptor-binding-domain of SARS-CoV-2,2021-10-13,
7DCC,Antibody,3C1,,7DCC_1;7DCC_2;7DCC_3,4.3,"S-3C1-F3b structure, all the three RBDs are in the up conformation and each of them associates with a 3C1 Fab",2020-12-02,10.1038/s41467-020-20465-w
7DCX,Antibody,3C1,,7DCX_1;7DCX_2;7DCX_3,5.9,"S-3C1-F3a structure, two RBDs are up and one RBD is down, each RBD binds with a 3C1 fab.",2020-12-02,10.1038/s41467-020-20465-w
7DD2,Antibody,3C1,,7DD2_1;7DD2_2,5.6,"S-3C1-F2 structure, two RBDs are up and one RBD is down, the two up RBD bind with a 3C1 fab.",2020-12-02,10.1038/s41467-020-20465-w
7DD8,Antibody,3C1,,7DD8_1,7.5,"S-3C1-F1 structure, one RBD is up and two RBDs are down, the up RBD binds with a 3C1 fab",2020-12-02,10.1038/s41467-020-20465-w
7DEO,Antibody,PR1077,,7DEO_1;7DEO_2,2.5,Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody scFv,2021-03-31,10.1371/journal.pbio.3001209
7DET,Antibody,PR961,,7DET_1;7DET_2,2.2,Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody scFv,2021-03-31,10.1371/journal.pbio.3001209
7DEU,Antibody,PR953,,7DEU_1,2.1,Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody scFv,2021-03-31,10.1371/journal.pbio.3001209
7DJZ,Antibody,MW01,,7DJZ_1,2.397,Crystal structure of SARS-CoV-2 Spike RBD in complex with MW01 Fab,2021-06-09,
7DK0,Antibody,MW05,,7DK0_1,3.199,Crystal structure of SARS-CoV-2 Spike RBD in complex with MW05 Fab,2021-06-09,
7DK4,Antibody,2H2,,7DK4_1;7DK4_2;7DK4_3,3.8,"S-2H2-F3a structure, two RBDs are up and one RBD is down, each RBD binds with a 2H2 Fab.",2020-12-02,10.1038/s41467-020-20465-w
7DK5,Antibody,2H2,,7DK5_1,13.5,"S-2H2-F1 structure, one RBD is up and two RBDs are down, only up RBD binds with a 2H2 Fab",2020-12-02,10.1038/s41467-020-20465-w
7DK6,Antibody,2H2,,7DK6_1;7DK6_2,4.3,"S-2H2-F2 structure, two RBDs are up and one RBD is down, each up RBD binds with a 2H2 Fab.",2020-12-02,10.1038/s41467-020-20465-w
7DK7,Antibody,2H2,,7DK7_1;7DK7_2;7DK7_3,9.7,"S-2H2-F3b structure, three RBDs are up and each RBD binds with a 2H2 Fab.",2020-12-02,10.1038/s41467-020-20465-w
7DPM,Antibody,MW06,,7DPM_1;7DPM_2;7DPM_3;7DPM_4,3.304,Crystal structure of SARS-CoV-2 Spike RBD in complex with MW06 Fab,2021-02-17,10.1080/19420862.2021.1953683
7DX4,Antibody,FC08,,7DX4_1,3.6,The structure of FC08 Fab-hA.CE2-RBD complex,2021-04-21,
7DZX,Antibody,8D2,,7DZX_1,3.53,Spike protein from SARS-CoV2 with Fab fragment of enhancing antibody 8D2,2021-06-02,10.1016/j.cell.2021.05.032
7DZY,Antibody,2490,,7DZY_1;7DZY_2;7DZY_3,3.6,Spike protein from SARS-CoV2 with Fab fragment of enhancing antibody 2490,2021-06-02,10.1016/j.cell.2021.05.032
7E23,Antibody,CA521,,,3.3,SARS-CoV-2 spike in complex with the CA521 neutralizing antibody Fab (focused refinement on Fab-RBD),2021-05-05,10.1038/s42003-021-02029-w
7E39,Antibody,Ab4,,,3.7,SARS-CoV-2 spike in complex with the Ab4 neutralizing antibody (State 3),2021-09-01,10.1038/s41421-021-00292-z
7E3B,Antibody,Ab5,,7E3B_1,4.2,SARS-Cov-2 spike in complex with the Ab5 neutralizing antibody (focused refinement on Fab-RBD),2021-09-01,10.1038/s41421-021-00292-z
7E3C,Antibody,Ab1,,7E3C_1,4.2,SARS-CoV-2 spike in complex with the Ab1 neutralizing antibody (focused refinement on Fab-RBD),2021-09-01,10.1038/s41421-021-00292-z
7E3K,Antibody,13G9,,7E3K_1;7E3K_2;7E3K_3,3.9,Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants,2021-09-15,
7E3L,Antibody,58G6,,7E3L_1;7E3L_2;7E3L_3,3.6,Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants,2021-09-15,
7E3O,Antibody,nCoV617,,7E3O_1,2.51,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody nCoV617,2021-09-15,
7E5O,Antibody,NT-193,,7E5O_1,2.8,Crystal structure of SARS-CoV-2 RBD in complex with antibody NT-193,2021-09-08,
7E5R,Antibody,FC05,"Q,P,R,S,W,X",7E5R_2;7E5R_4;7E5R_9,"3.6, 3.6",SARS-CoV-2 S trimer with three-antibody cocktail complex,2021-10-13,10.1038/s41422-021-00497-7
7E5R,Antibody,H014,"D,E,H,L,N,O",7E5R_1;7E5R_5;7E5R_7,"3.6, 3.6",SARS-CoV-2 S trimer with three-antibody cocktail complex,2021-10-13,10.1038/s41422-021-00497-7
7E5R,Antibody,P17,"I,K,M,T,U,V",7E5R_3;7E5R_6;7E5R_8,"3.6, 3.6",SARS-CoV-2 S trimer with three-antibody cocktail complex,2021-10-13,10.1038/s41422-021-00497-7
7E5S,Antibody,FC05,"N,Q,P,S,U,V",7E5S_2;7E5S_3;7E5S_6,"3.6, 3.6",SARS-CoV-2 S trimer with four-antibody cocktail complex,2021-11-17,10.1038/s41422-021-00497-7
7E5S,Antibody,H014,"D,E,H,L",7E5S_5;7E5S_7,"3.6, 3.6",SARS-CoV-2 S trimer with four-antibody cocktail complex,2021-11-17,10.1038/s41422-021-00497-7
7E5S,Antibody,HB27,"O,R",7E5S_1,"3.6, 3.6",SARS-CoV-2 S trimer with four-antibody cocktail complex,2021-11-17,10.1038/s41422-021-00497-7
7E5S,Antibody,P17,"I,J,K,T",7E5S_4;7E5S_8,"3.6, 3.6",SARS-CoV-2 S trimer with four-antibody cocktail complex,2021-11-17,10.1038/s41422-021-00497-7
7E5Y,Antibody,2B11,,7E5Y_1;7E5Y_2,3.59,Molecular basis for neutralizing antibody 2B11 targeting SARS-CoV-2 RBD,2021-06-23,
7E7X,Antibody,N11,,7E7X_1;7E7X_2,2.78,SARS-CoV-2 Spike Protein N terminal domain in Complex with N11 Fab,2021-06-09,10.1038/s41422-021-00514-9
7E7Y,Antibody,BD-623,,7E7Y_1;7E7Y_2,2.41,Crystal structure of the SARS-CoV-2 S RBD in complex with BD-623 Fab,2021-06-09,10.1038/s41422-021-00514-9
7E86,Antibody,BD-508,,,2.9,Crystal structure of the SARS-CoV-2 S RBD in complex with BD-508 Fab,2021-06-09,10.1038/s41422-021-00514-9
7E88,Antibody,BD-515,,,3.14,Crystal structure of the SARS-CoV-2 S RBD in complex with BD-515 Fab,2021-06-09,10.1038/s41422-021-00514-9
7E8C,Antibody,604,"D,E,N,O,P,Q",7E8C_3;7E8C_5;7E8C_7,3.16,SARS-CoV-2 S-6P in complex with 9 Fabs,2021-06-09,10.1038/s41422-021-00514-9
7E8C,Antibody,368-2,"a,I,J,K,M,Z",7E8C_1;7E8C_4;7E8C_8,3.16,SARS-CoV-2 S-6P in complex with 9 Fabs,2021-06-09,10.1038/s41422-021-00514-9
7E8C,Antibody,N9,"H,L,S,T,U,V",7E8C_2;7E8C_6;7E8C_9,3.16,SARS-CoV-2 S-6P in complex with 9 Fabs,2021-06-09,10.1038/s41422-021-00514-9
7E8F,Antibody,N9,,7E8F_1;7E8F_2;7E8F_3,3.18,SARS-CoV-2 NTD in complex with N9 Fab,2021-06-09,10.1038/s41422-021-00514-9
7E8M,Antibody,P2C-1F11,,7E8M_1,2.09,Crystal structure of SARS-CoV-2 antibody P2C-1F11 with mutated RBD,2021-05-26,
7EAM,Antibody,7D6,,7EAM_1;7EAM_2,1.4,immune complex of SARS-CoV-2 RBD and cross-neutralizing antibody 7D6,2021-03-17,
7EAN,Antibody,6D6,,7EAN_1,1.91,immune complex of SARS-CoV-2 RBD and cross-neutralizing antibody 6D6,2021-03-31,10.1038/s41467-021-25997-3
7EH5,Antibody,RBD-chAb15,"D,E,F,O,P,Q",7EH5_2;7EH5_3;7EH5_5,4,"Cryo-EM structure of SARS-CoV-2 S-D614G variant in complex with neutralizing antibodies, RBD-chAb15 and RBD-chAb45",2021-09-01,10.1038/s41594-021-00652-z
7EH5,Antibody,RBD-chAb45,"H,I,J,L,M,N",7EH5_1;7EH5_4;7EH5_6,4,"Cryo-EM structure of SARS-CoV-2 S-D614G variant in complex with neutralizing antibodies, RBD-chAb15 and RBD-chAb45",2021-09-01,10.1038/s41594-021-00652-z
7EJ4,Antibody,RBD-chAb-25,,7EJ4_1;7EJ4_2;7EJ4_3,3.6,Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody RBD-chAb-25,2021-06-23,
7EJ5,Antibody,RBD-chAb-45,,7EJ5_1;7EJ5_2;7EJ5_3,3.5,Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody RBD-chAb-45,2021-06-23,
7EY0,Antibody,BD-744,"A,B",,3.2,Local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-813 Fab and BD-744 Fab,2021-09-08,10.1038/s41422-021-00555-0
7EY0,Antibody,BD-813,"H,L",,3.2,Local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-813 Fab and BD-744 Fab,2021-09-08,10.1038/s41422-021-00555-0
7EY4,Antibody,BD-667,,,"3.69, 3.69",Local CryoEM of the SARS-CoV-2 S6PV2 in complex with BD-667,2021-09-08,10.1038/s41422-021-00555-0
7EY5,Antibody,BD-771,"H,L",7EY5_2,3.4,Local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-771 Fab and BD-821 Fab,2021-09-08,10.1038/s41422-021-00555-0
7EY5,Antibody,BD-821,"B,C",7EY5_1,3.4,Local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-771 Fab and BD-821 Fab,2021-09-08,10.1038/s41422-021-00555-0
7EYA,Antibody,BD-804,,7EYA_1,3.77,Local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-804 Fab,2021-09-08,10.1038/s41422-021-00555-0
7EZV,Antibody,BD-812,,7EZV_1;7EZV_2,3.3,local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-812 Fab and BD-836 Fab,2021-09-08,10.1038/s41422-021-00555-0
7F62,Antibody,chAb-25,,7F62_1,3.6,Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody chAb-25 (Focused refinement of S-RBD and chAb-25 region),2021-08-04,
7F63,Antibody,chAb-45,,7F63_1,3.9,Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody chAb-45 (Focused refinement of S-RBD and chAb-45 region),2021-08-04,
7JMO,Antibody,COVA2-04,,7JMO_1,2.359,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody COVA2-04,2020-08-26,10.1101/2020.07.26.222232
7JMP,Antibody,COVA2-39,,7JMP_1,1.712,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody COVA2-39,2020-08-26,10.1101/2020.07.26.222232
7JMW,Antibody,COVA1-16,,7JMW_1,2.89,Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with cross-neutralizing antibody COVA1-16 Fab,2020-10-14,10.1101/2020.08.02.233536
7JV2,Antibody,S2H13,,7JV2_1,3.5,SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody Fab fragment (local refinement of the receptor-binding motif and Fab variable domains),2020-10-14,10.1016/j.cell.2020.09.037
7JV4,Antibody,S2H13,,7JV4_1;7JV4_2;7JV4_3,3.4,SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody (one RBD open),2020-10-14,10.1016/j.cell.2020.09.037
7JV6,Antibody,S2H13,,7JV6_1;7JV6_2;7JV6_3,3,SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody (closed conformation),2020-10-14,10.1016/j.cell.2020.09.037
7JVA,Antibody,S2A4,,7JVA_1,3.6,SARS-CoV-2 spike in complex with the S2A4 neutralizing antibody Fab fragment (local refinement of the receptor-binding domain and Fab variable domains),2020-10-14,10.1016/j.cell.2020.09.037
7JVC,Antibody,S2A4,,7JVC_1;7JVC_2;7JVC_3,3.3,SARS-CoV-2 spike in complex with the S2A4 neutralizing antibody Fab fragment,2020-10-14,10.1016/j.cell.2020.09.037
7JW0,Antibody,S304,,7JW0_1;7JW0_2;7JW0_3,4.3,SARS-CoV-2 spike in complex with the S304 neutralizing antibody Fab fragment,2020-10-14,10.1016/j.cell.2020.09.037
7JX3,Antibody,S2H14,"C,D",7JX3_1,2.65,Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology,2020-10-14,10.1016/j.cell.2020.09.037
7JX3,Antibody,S304,"H,L",7JX3_3,2.65,Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology,2020-10-14,10.1016/j.cell.2020.09.037
7JX3,Antibody,S309,"A,B",7JX3_2,2.65,Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology,2020-10-14,10.1016/j.cell.2020.09.037
7K43,Antibody,S2M11,,7K43_1;7K43_2;7K43_3,2.6,SARS-CoV-2 spike in complex with the S2M11 neutralizing antibody Fab fragment,2020-10-07,10.1126/science.abe3354
7K45,Antibody,S2E12,,7K45_1,3.7,SARS-CoV-2 spike in complex with the S2E12 neutralizing antibody Fab fragment (local refinement of the RBD and Fab variable domains),2020-10-07,10.1126/science.abe3354
7K4N,Antibody,S2E12,,7K4N_1;7K4N_2;7K4N_3,3.3,SARS-CoV-2 spike in complex with the S2E12 neutralizing antibody Fab fragment,2020-10-07,10.1126/science.abe3354
7K8M,Antibody,C102,,7K8M_1,3.2,"Structure of the SARS-CoV-2 receptor binding domain in complex with the human neutralizing antibody Fab fragment, C102",2020-10-21,10.1038/s41586-020-2852-1
7K8S,Antibody,C002,,7K8S_1;7K8S_2;7K8S_3,3.4,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C002 (state 1)",2020-10-21,10.1038/s41586-020-2852-1
7K8T,Antibody,C002,,7K8T_1;7K8T_2;7K8T_3,3.4,"Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, C002 (State 2)",2020-10-21,10.1038/s41586-020-2852-1
7K8U,Antibody,C104,,7K8U_1,3.8,"Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, C104",2020-10-21,10.1038/s41586-020-2852-1
7K8V,Antibody,C110,,7K8V_1;7K8V_2,3.8,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C110",2020-10-21,10.1038/s41586-020-2852-1
7K8W,Antibody,C119,,7K8W_1;7K8W_2,3.6,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C119",2020-10-21,10.1038/s41586-020-2852-1
7K8X,Antibody,C121,,7K8X_1;7K8X_2,"3.9, 3.9","Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C121 (State 1)",2020-10-21,10.1038/s41586-020-2852-1
7K8Y,Antibody,C121,,7K8Y_1,"4.4, 4.4","Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C121 (State 2)",2020-10-21,10.1038/s41586-020-2852-1
7K8Z,Antibody,C135,,7K8Z_1;7K8Z_2,3.5,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C135",2020-10-21,10.1038/s41586-020-2852-1
7K90,Antibody,C144,,7K90_1;7K90_2;7K90_3,3.24,"Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, C144",2020-10-21,10.1038/s41586-020-2852-1
7K9H,Antibody,2B04,,7K9H_1;7K9H_2,3.2,"SARS-CoV-2 Spike in complex with neutralizing Fab 2B04 (one up, two down conformation)",2021-09-29,10.1016/j.celrep.2021.109881
7K9I,Antibody,2B04,,7K9I_1,3.3,SARS-CoV-2 Spike RBD in complex with neutralizing Fab 2B04 (local refinement),2021-09-29,10.1016/j.celrep.2021.109881
7K9J,Antibody,2H04,,7K9J_1;7K9J_2;7K9J_3,3,SARS-CoV-2 Spike in complex with neutralizing Fab 2H04 (three down conformation),2021-09-29,10.1016/j.celrep.2021.109881
7K9K,Antibody,2H04,,7K9K_1,3.14,SARS-CoV-2 Spike RBD in complex with neutralizing Fab 2H04 (local refinement),2021-09-29,10.1016/j.celrep.2021.109881
7K9Z,Antibody,52,"H,L",7K9Z_1,2.95,Crystal structure of SARS-CoV-2 receptor binding domain in complex with the Fab fragments of neutralizing antibodies 298 and 52,2020-10-28,10.1038/s41467-021-23825-2
7K9Z,Antibody,298,"A,B",7K9Z_2,2.95,Crystal structure of SARS-CoV-2 receptor binding domain in complex with the Fab fragments of neutralizing antibodies 298 and 52,2020-10-28,10.1038/s41467-021-23825-2
7KFV,Antibody,C1A-B12,,7KFV_1;7KFV_2;7KFV_3,2.102,Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-B12 Fab),2020-12-02,10.1101/2020.11.13.381533
7KFW,Antibody,C1A-B3,,7KFW_1;7KFW_2;7KFW_3,2.792,Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-B3 Fab),2020-12-02,10.1101/2020.11.13.381533
7KFX,Antibody,C1A-C2,,7KFX_1,2.226,Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-C2 Fab),2020-12-02,10.1101/2020.11.13.381533
7KFY,Antibody,C1A-F10,,7KFY_1,2.157,Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-F10 Fab),2020-12-02,10.1101/2020.11.13.381533
7KKK,Antibody,Nb6,,,3.03,SARS-CoV-2 Spike in complex with neutralizing nanobody Nb6,2020-11-11,10.1126/science.abe3255
7KKL,Antibody,mNb6,,,2.85,SARS-CoV-2 Spike in complex with neutralizing nanobody mNb6,2020-11-11,10.1126/science.abe3255
7KLG,Antibody,15033,,7KLG_1;7KLG_2,3.2,SARS-CoV-2 RBD in complex with Fab 15033,2021-02-10,10.1016/j.jmb.2021.167177
7KLH,Antibody,15033-7,,7KLH_1;7KLH_2,3,SARS-CoV-2 RBD in complex with Fab 15033-7,2021-02-10,10.1016/j.jmb.2021.167177
7KMG,Antibody,LY-CoV555,,7KMG_1;7KMG_2,2.16,LY-CoV555 neutralizing antibody against SARS-CoV-2,2021-01-27,10.1126/scitranslmed.abf1906
7KMH,Antibody,LY-CoV488,,7KMH_1,1.72,LY-CoV488 neutralizing antibody against SARS-CoV-2,2021-01-27,10.1126/scitranslmed.abf1906
7KMI,Antibody,LY-CoV481,,7KMI_1,1.73,LY-CoV481 neutralizing antibody against SARS-CoV-2,2021-01-27,10.1126/scitranslmed.abf1906
7KMK,Antibody,15033-7,,7KMK_1;7KMK_2,4.2,"cryo-EM structure of SARS-CoV-2 spike in complex with Fab 15033-7, two RBDs bound",2021-02-10,10.1016/j.jmb.2021.167177
7KML,Antibody,15033-7,,7KML_1;7KML_2;7KML_3,3.8,"cryo-EM structure of SARS-CoV-2 spike in complex with Fab 15033-7, three RBDs bound",2021-02-10,10.1016/j.jmb.2021.167177
7KN3,Antibody,S-B8,,7KN3_1;7KN3_2,2.251,Crystal structure of SARS-CoV-2 spike protein receptor-binding domain complexed with a pre-pandemic antibody S-B8 Fab,2021-09-22,10.1002/advs.202102181
7KN4,Antibody,S-E6,,7KN4_1;7KN4_2,2.7,Crystal structure of SARS-CoV-2 spike protein receptor-binding domain complexed with a pre-pandemic antibody S-E6 Fab,2021-09-22,10.1002/advs.202102181
7KN6,Antibody,CC12.3,"H,L",7KN6_1,2.55,Crystal structure of SARS-CoV-2 receptor binding domain complexed with nanobody VHH V and antibody Fab CC12.3,2021-01-20,10.1126/science.abe6230
7KN7,Antibody,CC12.3,"H,L",7KN7_1,2.73,Crystal structure of SARS-CoV-2 receptor binding domain complexed with nanobody VHH W and antibody Fab CC12.3,2021-01-20,10.1126/science.abe6230
7KQE,Antibody,3D11,,7KQE_1;7KQE_2;7KQE_3,2.88,SARS-CoV-2 spike glycoprotein:Fab 3D11 complex,2021-05-26,10.1016/j.cell.2021.04.033
7KS9,Antibody,910-30,,7KS9_1,4.75,Cryo-EM structure of prefusion SARS-CoV-2 spike glycoprotein in complex with 910-30 Fab,2021-02-10,10.1101/2020.12.31.424987
7KXJ,Antibody,15033-7,,7KXJ_1;7KXJ_2;7KXJ_3,6.4,"SARS-CoV-2 spike protein in complex with Fab 15033-7, 3-""up"", asymmetric",2021-02-03,10.1016/j.jmb.2021.167177
7KXK,Antibody,15033-7,,7KXK_1;7KXK_2;7KXK_3,5,"SARS-CoV-2 spike protein in complex with Fab 15033-7, 2-""up""-1-""down"" conformation",2021-02-03,10.1016/j.jmb.2021.167177
7KZB,Antibody,CR3014-C8,"H,L",7KZB_2,2.83,Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1antibodies,2021-02-03,10.1080/19420862.2021.1922134
7KZB,Antibody,CR3022-B6,"A,B",7KZB_1,2.83,Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1antibodies,2021-02-03,10.1080/19420862.2021.1922134
7L02,Antibody,2G12,,7L02_1,3.2,Cryo-EM structure of SARS-CoV-2 2P S ectodomain bound to one copy of domain-swapped antibody 2G12,2020-12-30,10.1016/j.cell.2021.04.042
7L06,Antibody,2G12,,7L06_1;7L06_2,3.3,Cryo-EM structure of SARS-CoV-2 2P S ectodomain bound to two copies of domain-swapped antibody 2G12,2020-12-30,10.1016/j.cell.2021.04.042
7L09,Antibody,2G12,,7L09_1,3.1,Cryo-EM structure of SARS-CoV-2 2P S ectodomain bound domain-swapped antibody 2G12 from masked 3D refinement,2020-12-30,10.1016/j.cell.2021.04.042
7L0N,Antibody,S304,"H,L,M,N",7L0N_2;7L0N_3,2.78,Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity,2021-02-17,10.1016/j.cell.2021.01.037
7L0N,Antibody,S309,"A,B,C,D",7L0N_1;7L0N_4,2.78,Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity,2021-02-17,10.1016/j.cell.2021.01.037
7L2C,Antibody,2-51,,7L2C_1;7L2C_2,3.65,Crystallographic structure of neutralizing antibody 2-51 in complex with SARS-CoV-2 spike N-terminal domain (NTD),2021-02-10,10.1016/j.chom.2021.03.005
7L2D,Antibody,1-87,,7L2D_1,3.55,Cryo-EM structure of NTD-directed neutralizing antibody 1-87 in complex with prefusion SARS-CoV-2 spike glycoprotein,2021-03-24,10.1016/j.chom.2021.03.005
7L2E,Antibody,4-18,,7L2E_1;7L2E_2;7L2E_3,2.97,Cryo-EM structure of NTD-directed neutralizing antibody 4-18 in complex with prefusion SARS-CoV-2 spike glycoprotein,2021-03-24,10.1016/j.chom.2021.03.005
7L2F,Antibody,5-24,,7L2F_1;7L2F_2;7L2F_3,3.9,Cryo-EM structure of NTD-directed neutralizing antibody 5-24 in complex with prefusion SARS-CoV-2 spike glycoprotein,2021-03-24,10.1016/j.chom.2021.03.005
7L3N,Antibody,LY-CoV555,,7L3N_1,3.27,SARS-CoV 2 Spike Protein bound to LY-CoV555,2021-02-03,10.1101/2020.09.30.318972
7L56,Antibody,2-43,,7L56_1;7L56_2;7L56_3,3.6,Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-43,2021-04-14,10.1016/j.celrep.2021.108950
7L57,Antibody,2-15,,7L57_1,5.87,Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-15,2021-04-14,10.1016/j.celrep.2021.108950
7L58,Antibody,H4,,7L58_1,5.07,Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab H4,2021-04-14,10.1016/j.celrep.2021.108950
7L5B,Antibody,2-15,,7L5B_1,3.18,Crystallographic structure of neutralizing antibody 2-15 in complex with SARS-CoV-2 spike receptor-binding Domain (RBD).,2021-02-10,10.1016/j.celrep.2021.108950
7L7D,Antibody,AZD8895,,7L7D_1,2.5,Crystal structure of SARS-CoV-2 spike RBD in complex with human monoclonal antibody AZD8895,2021-09-01,
7L7E,Antibody,AZD1061,"C,D,E,F,M,N,O,P",7L7E_1;7L7E_4;7L7E_6;7L7E_8,3,Crystal structure of SARS-CoV-2 spike RBD in complex with human monoclonal antibodies AZD8895 and AZD1061,2021-09-01,
7L7E,Antibody,AZD8895,"A,B,H,I,J,L,T,U",7L7E_2;7L7E_3;7L7E_5;7L7E_7,3,Crystal structure of SARS-CoV-2 spike RBD in complex with human monoclonal antibodies AZD8895 and AZD1061,2021-09-01,
7LAA,Antibody,DH1041,,7LAA_1,3.42,Structure of SARS-CoV-2 S protein in complex with Receptor Binding Domain antibody DH1041,2021-03-17,10.1016/j.cell.2021.06.021
7LAB,Antibody,DH1052,,7LAB_1;7LAB_2;7LAB_3,"2.97, 2.97",Structure of SARS-CoV-2 S protein in complex with N-terminal domain antibody DH1052,2021-03-10,10.1016/j.cell.2021.06.021
7LCN,Antibody,DH1050.1,,7LCN_1;7LCN_2;7LCN_3,"3.35, 3.35",Structure of SARS-CoV-2 S protein in complex with N-terminal domain antibody DH1050.1,2021-01-27,10.1016/j.cell.2021.06.021
7LD1,Antibody,DH1047,,7LD1_1;7LD1_2;7LD1_3,"3.4, 3.4",Structure of SARS-CoV-2 S protein in complex with Receptor Binding Domain antibody DH1047,2021-01-27,10.1016/j.cell.2021.06.021
7LJR,Antibody,DH1043,,7LJR_1,3.66,SARS-CoV-2 Spike Protein Trimer bound to DH1043 fab,2021-03-31,10.1101/2020.12.31.424729
7LM8,Antibody,COVA1-16,"H,L",7LM8_1,1.936,Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with two cross-neutralizing antibodies CV38-142 and COVA1-16 Fabs isolated from COVID-19 patients,2021-03-31,10.1101/2021.02.11.430866
7LM8,Antibody,CV38-142,"M,N",7LM8_2,1.936,Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with two cross-neutralizing antibodies CV38-142 and COVA1-16 Fabs isolated from COVID-19 patients,2021-03-31,10.1101/2021.02.11.430866
7LOP,Antibody,CR3022,"B,C,W,V",7LOP_1;7LOP_3,2.246,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CV05-163 and CR3022,2021-03-03,10.1126/science.abh1139
7LOP,Antibody,CV05-163,"H,L,X,Y",7LOP_2;7LOP_4,2.246,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CV05-163 and CR3022,2021-03-03,10.1126/science.abh1139
7LQ7,Antibody,COVA1-16,"P,Q,T,U,y,z",7LQ7_2;7LQ7_3;7LQ7_5,3.4,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CV503 and COVA1-16,2021-09-15,
7LQ7,Antibody,CV503,"C,D,F,G,H,L",7LQ7_1;7LQ7_4;7LQ7_6,3.4,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CV503 and COVA1-16,2021-09-15,
7LQV,Antibody,4-8,,7LQV_1;7LQV_2;7LQV_3,3.25,Cryo-EM structure of NTD-directed neutralizing antibody 4-8 Fab in complex with SARS-CoV-2 S2P spike,2021-03-24,
7LQW,Antibody,2-17,,7LQW_1,4.47,Cryo-EM structure of NTD-directed neutralizing antibody 2-17 Fab in complex with SARS-CoV-2 S2P spike,2021-03-24,10.1016/j.chom.2021.03.005
7LRS,Antibody,A23-58.1,,7LRS_1,3.89,Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody A23-58.1 that targets the receptor-binding domain,2021-07-14,10.1126/science.abh1766
7LRT,Antibody,A23-58.1,,7LRT_1;7LRT_2;7LRT_3,3.54,Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody A23-58.1 that targets the receptor-binding domain,2021-07-14,10.1126/science.abh1766
7LS9,Antibody,1-57,,7LS9_1;7LS9_2;7LS9_3,3.42,Cryo-EM structure of neutralizing antibody 1-57 in complex with prefusion SARS-CoV-2 spike glycoprotein,2021-03-17,10.1016/j.str.2021.05.014
7LSS,Antibody,2-7,,7LSS_1,3.72,Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-7,2021-03-17,10.1016/j.str.2021.05.014
7LXW,Antibody,S2X333,,7LXW_1,"2.8, 2.8",SARS-CoV-2 S/S2M11/S2X333 Local Refinement,2021-04-14,10.1016/j.cell.2021.03.028
7LXX,Antibody,S2L28,,7LXX_1,3,SARS-CoV-2 S/S2M11/S2L28 Local Refinement,2021-04-14,10.1016/j.cell.2021.03.028
7LXY,Antibody,S2M11,"C,D,E,F,K,M",7LXY_1;7LXY_3;7LXY_6,2.2,SARS-CoV-2 S/S2M11/S2X333 Global Refinement,2021-04-14,10.1016/j.cell.2021.03.028
7LXY,Antibody,S2X333,"G,H,I,L,N,O",7LXY_2;7LXY_4;7LXY_5,2.2,SARS-CoV-2 S/S2M11/S2X333 Global Refinement,2021-04-14,10.1016/j.cell.2021.03.028
7LXZ,Antibody,S2L28,"G,H,I,J,N,O",7LXZ_1;7LXZ_3;7LXZ_5,2.6,SARS-CoV-2 S/S2M11/S2L28 Global Refinement,2021-04-14,10.1016/j.cell.2021.03.028
7LXZ,Antibody,S2M11,"C,D,E,F,L,M",7LXZ_2;7LXZ_4;7LXZ_6,2.6,SARS-CoV-2 S/S2M11/S2L28 Global Refinement,2021-04-14,10.1016/j.cell.2021.03.028
7LY0,Antibody,S2M28,,7LY0_1,2.6,SARS-CoV-2 S/S2M11/S2M28 Local Refinement,2021-04-14,10.1016/j.cell.2021.03.028
7LY2,Antibody,S2M11,"C,D,E,F,K,M",7LY2_2;7LY2_3;7LY2_6,2.5,SARS-CoV-2 S/S2M11/S2M28 Global Refinement,2021-04-14,10.1016/j.cell.2021.03.028
7LY2,Antibody,S2M28,"G,H,I,L,N,O",7LY2_1;7LY2_4;7LY2_5,2.5,SARS-CoV-2 S/S2M11/S2M28 Global Refinement,2021-04-14,10.1016/j.cell.2021.03.028
7LY3,Antibody,S2M28,,7LY3_1;7LY3_2,3,Crystal structure of SARS-CoV-2 S NTD bound to S2M28 Fab,2021-04-14,10.1016/j.cell.2021.03.028
7M3I,Antibody,CV2-75,,7M3I_1;7M3I_2,2.8,"Structure of SARS-CoV-2 spike protein receptor binding domain in complex with a neutralizing antibody, CV2-75 Fab",2021-05-12,10.1016/j.celrep.2021.109353
7M42,Antibody,REGN10985,"C,D",7M42_1,3.3,Complex of SARS-CoV-2 receptor binding domain with the Fab fragments of neutralizing antibodies REGN10985 and REGN10989,2021-07-28,10.1016/j.cell.2021.06.002
7M42,Antibody,REGN10989,"A,B",7M42_2,3.3,Complex of SARS-CoV-2 receptor binding domain with the Fab fragments of neutralizing antibodies REGN10985 and REGN10989,2021-07-28,10.1016/j.cell.2021.06.002
7M53,Antibody,B6,,,1.4,B6 Fab fragment bound to the SARS-CoV/SARS-CoV-2 spike stem helix peptide,2021-05-26,10.1038/s41594-021-00596-4
7M6D,Antibody,BG4-25,"H,L",7M6D_2,3.1,Structure of the SARS-CoV-2 RBD in complex with neutralizing antibodies BG4-25 and CR3022,2021-05-05,10.1016/j.cell.2021.04.032
7M6D,Antibody,CR3022,"A,B",7M6D_1,3.1,Structure of the SARS-CoV-2 RBD in complex with neutralizing antibodies BG4-25 and CR3022,2021-05-05,10.1016/j.cell.2021.04.032
7M6E,Antibody,BG10-19,,7M6E_1;7M6E_2;7M6E_3,3.3,"Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, BG10-19",2021-05-05,10.1016/j.cell.2021.04.032
7M6F,Antibody,BG1-22,,7M6F_1;7M6F_2,3.9,"Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, BG1-22",2021-05-05,10.1016/j.cell.2021.04.032
7M6G,Antibody,BG7-15,,7M6G_1;7M6G_2,3.7,"Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, BG7-15",2021-05-05,10.1016/j.cell.2021.04.032
7M6H,Antibody,BG7-20,,7M6H_1;7M6H_2,4,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, BG7-20",2021-05-05,10.1016/j.cell.2021.04.032
7M6I,Antibody,BG1-24,,7M6I_1;7M6I_2,4,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, BG1-24",2021-05-05,10.1016/j.cell.2021.04.032
7M71,Antibody,5A6,,7M71_1,2.66,SARS-CoV-2 Spike:5A6 Fab complex I focused refinement,2021-05-26,10.1016/j.cell.2021.04.033
7M7B,Antibody,3D11,,7M7B_1,2.95,SARS-CoV-2 Spike:Fab 3D11 complex focused refinement,2021-05-26,10.1016/j.cell.2021.04.033
7M7W,Antibody,S2H97,"C,D,E,F",7M7W_1;7M7W_3,2.65,Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape,2021-05-05,10.1038/s41586-021-03807-6
7M7W,Antibody,S2X259,"A,B,H,L",7M7W_2;7M7W_4,2.65,Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape,2021-05-05,10.1038/s41586-021-03807-6
7M8J,Antibody,CM25,,7M8J_1,3.48,SARS-CoV-2 S-NTD + Fab CM25,2021-05-19,10.1126/science.abg5268
7MF1,Antibody,47D1,,7MF1_1,2.092,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody 47D1,2021-05-12,10.1016/j.celrep.2021.109109
7MJH,Antibody,VH ab8,,,2.66,Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to VH ab8,2021-05-12,10.1371/journal.pbio.3001237
7MJI,Antibody,VH ab8,,,2.81,Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to VH ab8 (focused refinement of RBD and VH ab8),2021-05-12,10.1371/journal.pbio.3001237
7MJJ,Antibody,ab1,,7MJJ_1;7MJJ_2,3.32,Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to Fab ab1 (class 1),2021-05-12,10.1371/journal.pbio.3001237
7MJK,Antibody,ab1,,7MJK_1;7MJK_2;7MJK_3,2.73,Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to Fab ab1 (class 2),2021-05-12,10.1371/journal.pbio.3001237
7MJL,Antibody,ab1,,7MJL_1,2.95,Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to Fab ab1 (focused refinement of RBD and Fab ab1),2021-05-12,10.1371/journal.pbio.3001237
7MKL,Antibody,SARS2-38,,7MKL_1,3.2,SARS-CoV-2 Spike in complex with neutralizing Fab SARS2-38 (three down conformation),2021-05-12,10.1016/j.immuni.2021.08.016
7MKM,Antibody,SARS2-38,,7MKM_1,3.16,SARS-CoV-2 Spike RBD in complex with neutralizing Fab SARS2-38 (local refinement),2021-05-12,10.1016/j.immuni.2021.08.016
7MLZ,Antibody,B1-182.1,,7MLZ_1,3.71,Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody B1-182.1 that targets the receptor-binding domain,2021-07-28,10.1126/science.abh1766
7MM0,Antibody,B1-182.1,,7MM0_1,3.15,Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody B1-182.1 that targets the receptor-binding domain,2021-07-28,10.1126/science.abh1766
7MMO,Antibody,LY-CoV1404,,7MMO_1;7MMO_2,2.427,LY-CoV1404 neutralizing antibody against SARS-CoV-2,2021-05-12,10.1101/2021.04.30.442182
7MZF,Antibody,PDI 37,,7MZF_1,2.493,SARS-CoV-2 receptor binding domain bound to Fab PDI 37,2021-10-06,10.1016/j.celrep.2021.109822
7MZG,Antibody,PDI 42,,7MZG_1,2,SARS-CoV-2 receptor binding domain bound to Fab PDI 42,2021-10-06,10.1016/j.celrep.2021.109822
7MZH,Antibody,WCSL 119,,7MZH_1;7MZH_2,2.1,SARS-CoV-2 receptor binding domain bound to Fab WCSL 119,2021-10-06,10.1016/j.celrep.2021.109822
7MZI,Antibody,WCSL 129,,7MZI_1,1.85,SARS-CoV-2 receptor binding domain bound to Fab WCSL 129,2021-10-06,10.1016/j.celrep.2021.109822
7MZJ,Antibody,PDI 93,"H,L,M,N",7MZJ_2;7MZJ_4,2.4,SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 and Fab PDI 93,2021-10-06,10.1016/j.celrep.2021.109822
7MZJ,Antibody,WCSL 129,"C,D,E,F",7MZJ_1;7MZJ_3,2.4,SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 and Fab PDI 93,2021-10-06,10.1016/j.celrep.2021.109822
7MZK,Antibody,PDI 96,"H,L,M,N",7MZK_1;7MZK_4,2.25,SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 and Fab PDI 96,2021-10-06,10.1016/j.celrep.2021.109822
7MZK,Antibody,WCSL 129,"C,D,E,F",7MZK_2;7MZK_3,2.25,SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 and Fab PDI 96,2021-10-06,10.1016/j.celrep.2021.109822
7MZL,Antibody,PDI 210,,7MZL_1,3.7,SARS-CoV-2 receptor binding domain bound to Fab PDI 210,2021-10-06,10.1016/j.celrep.2021.109822
7MZM,Antibody,PDI 215,,7MZM_1,2.3,SARS-CoV-2 receptor binding domain bound to Fab PDI 215,2021-10-06,10.1016/j.celrep.2021.109822
7MZN,Antibody,PDI 231,,7MZN_1,3.1,SARS-CoV-2 receptor binding domain bound to Fab PDI 231,2021-10-06,10.1016/j.celrep.2021.109822
7N3I,Antibody,C098,,7N3I_1,2.03,Crystal structure of the SARS-CoV-2 receptor binding domain in complex with the human neutralizing antibody Fab fragment C098,2021-08-04,10.1016/j.immuni.2021.07.008
7N4I,Antibody,WRAIR-2057,,7N4I_1,2.284,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody WRAIR-2057.,2021-10-06,10.1038/s41590-021-01068-z
7N4J,Antibody,WRAIR-2173,,7N4J_1,2.207,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody WRAIR-2173.,2021-10-06,10.1038/s41590-021-01068-z
7N4L,Antibody,WRAIR-2125,,7N4L_1,3.601,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody WRAIR-2125.,2021-11-10,10.1038/s41590-021-01068-z
7N4M,Antibody,WRAIR-2151,,7N4M_1,3.79,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody WRAIR-2151.,2021-11-10,10.1038/s41590-021-01068-z
7N5H,Antibody,2-36,,7N5H_1;7N5H_2;7N5H_3,3.24,Cryo-EM structure of broadly neutralizing antibody 2-36 in complex with prefusion SARS-CoV-2 spike glycoprotein,2021-11-03,10.1101/2021.10.13.464307
7N62,Antibody,C12C9,,7N62_1,4,SARS-CoV-2 Spike (2P) in complex with C12C9 Fab (NTD local reconstruction),2021-08-04,10.1101/2021.03.10.434840
7N64,Antibody,G32R7,,7N64_1,4.2,SARS-CoV-2 Spike (2P) in complex with G32R7 Fab (RBD and NTD local reconstruction),2021-08-04,10.1101/2021.03.10.434840
7N8H,Antibody,S2L20,"B,C,I,J,N,O",7N8H_2;7N8H_3;7N8H_5,2.3,SARS-CoV-2 S (B.1.429 / epsilon variant) + S2M11 + S2L20 Global Refinement,2021-07-14,10.1126/science.abi7994
7N8H,Antibody,S2M11,"D,E,G,H,L,M",7N8H_1;7N8H_4;7N8H_6,2.3,SARS-CoV-2 S (B.1.429 / epsilon variant) + S2M11 + S2L20 Global Refinement,2021-07-14,10.1126/science.abi7994
7N8I,Antibody,S2L20,,7N8I_1,3,SARS-CoV-2 S (B.1.429 / epsilon variant) + S2M11 + S2L20 (Local Refinement of the NTD/S2L20),2021-07-14,10.1126/science.abi7994
7ND3,Antibody,COVOX-40,,7ND3_1,3.7,EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-40 Fab,2021-03-03,10.1016/j.cell.2021.02.032
7ND4,Antibody,COVOX-88,,7ND4_1;7ND4_2;7ND4_3,3.6,EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-88 Fab,2021-03-03,10.1016/j.cell.2021.02.032
7ND5,Antibody,COVOX-150,,7ND5_1,3.4,EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-150 Fab,2021-03-03,10.1016/j.cell.2021.02.032
7ND6,Antibody,COVOX-40,,7ND6_1,7.3,EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-40 Fab,2021-03-03,10.1016/j.cell.2021.02.032
7ND7,Antibody,COVOX-316,,7ND7_1;7ND7_2;7ND7_3,3.6,EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-316 Fab,2021-03-03,10.1016/j.cell.2021.02.032
7ND8,Antibody,COVOX-384,,7ND8_1,3.5,EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-384 Fab,2021-03-03,10.1016/j.cell.2021.02.032
7ND9,Antibody,COVOX-253H55L,,7ND9_1,2.8,EM structure of SARS-CoV-2 Spike glycoprotein (one RBD up) in complex with COVOX-253H55L Fab,2021-03-03,
7NDA,Antibody,COVOX-253H55L,,7NDA_1,3.3,EM structure of SARS-CoV-2 Spike glycoprotein (all RBD down) in complex with COVOX-253H55L Fab,2021-03-03,
7NDB,Antibody,COVOX-253H165L,,7NDB_1,4.6,EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-253H165L Fab,2021-03-03,10.1016/j.cell.2021.02.032
7NDC,Antibody,COVOX-159,,7NDC_1;7NDC_2;7NDC_3,4.1,EM structure of SARS-CoV-2 Spike glycoprotein (all RBD down) in complex with COVOX-159,2021-03-03,10.1016/j.cell.2021.02.032
7NDD,Antibody,COVOX-159,,7NDD_1;7NDD_2;7NDD_3,4.2,EM structure of SARS-CoV-2 Spike glycoprotein (one RBD up) in complex with COVOX-159,2021-03-03,10.1016/j.cell.2021.02.032
7NEG,Antibody,COVOX-269,,7NEG_1,2.19,Crystal structure of the N501Y mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-269 Fab,2021-03-03,10.1016/j.cell.2021.02.033
7NEH,Antibody,COVOX-269,,7NEH_1,1.77,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-269 Fab,2021-03-03,10.1016/j.cell.2021.02.033
7NP1,Antibody,ION-360,,7NP1_1;7NP1_2;7NP1_3;7NP1_4,2.8,Crystal Structure of the SARS-CoV-2 Receptor Binding Domain in Complex with Antibody ION-360,2021-11-17,10.3389/fimmu.2021.678570
7NTC,Antibody,P008_056,,7NTC_1,3.6,Trimeric SARS-CoV-2 spike ectodomain bound to P008_056 Fab,2021-04-28,10.1126/sciadv.abg7607
7NX6,Antibody,COVOX-222,"A,B",7NX6_2,2.25,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,2021-04-07,10.1016/j.cell.2021.03.055
7NX6,Antibody,EY6A,"H,L",7NX6_1,2.25,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,2021-04-07,10.1016/j.cell.2021.03.055
7NX7,Antibody,COVOX-222,"A,B",7NX7_2,2.3,Crystal structure of the K417N mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,2021-04-07,10.1016/j.cell.2021.03.055
7NX7,Antibody,EY6A,"H,L",7NX7_1,2.3,Crystal structure of the K417N mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,2021-04-07,10.1016/j.cell.2021.03.055
7NX8,Antibody,COVOX-222,"A,B",7NX8_2,1.95,Crystal structure of the K417T mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,2021-04-07,10.1016/j.cell.2021.03.055
7NX8,Antibody,EY6A,"H,L",7NX8_1,1.95,Crystal structure of the K417T mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,2021-04-07,10.1016/j.cell.2021.03.055
7NX9,Antibody,COVOX-222,"A,B",7NX9_1,2.4,Crystal structure of the N501Y mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,2021-04-07,10.1016/j.cell.2021.03.055
7NX9,Antibody,EY6A,"H,L",7NX9_2,2.4,Crystal structure of the N501Y mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,2021-04-07,10.1016/j.cell.2021.03.055
7NXA,Antibody,COVOX-222,"A,B",7NXA_1,2.5,Crystal structure of the receptor binding domain of SARS-CoV-2 B.1.351 variant Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,2021-04-07,10.1016/j.cell.2021.03.055
7NXA,Antibody,EY6A,"H,L",7NXA_2,2.5,Crystal structure of the receptor binding domain of SARS-CoV-2 B.1.351 variant Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,2021-04-07,10.1016/j.cell.2021.03.055
7NXB,Antibody,COVOX-222,"A,B",7NXB_1,2.67,Crystal structure of the receptor binding domain of SARS-CoV-2 P.1 variant Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,2021-04-07,10.1016/j.cell.2021.03.055
7NXB,Antibody,EY6A,"H,L",7NXB_2,2.67,Crystal structure of the receptor binding domain of SARS-CoV-2 P.1 variant Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,2021-04-07,10.1016/j.cell.2021.03.055
7OR9,Antibody,COVOX-222,"A,B",7OR9_2,2.34,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and COVOX-278 Fabs,2021-07-07,10.1016/j.cell.2021.06.020
7OR9,Antibody,COVOX-278,"H,L",7OR9_1,2.34,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and COVOX-278 Fabs,2021-07-07,10.1016/j.cell.2021.06.020
7ORA,Antibody,COVOX-253,"F,G,H,L",7ORA_1;7ORA_4,2.6,Crystal structure of the T478K mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-45 and COVOX-253 Fabs,2021-07-07,10.1016/j.cell.2021.06.020
7ORA,Antibody,COVOX-45,"A,B,D,E",7ORA_2;7ORA_3,2.6,Crystal structure of the T478K mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-45 and COVOX-253 Fabs,2021-07-07,10.1016/j.cell.2021.06.020
7ORB,Antibody,COVOX-253,"C,D,H,L",7ORB_1;7ORB_4,2.5,Crystal structure of the L452R mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-75 and COVOX-253 Fabs,2021-07-07,10.1016/j.cell.2021.06.020
7ORB,Antibody,COVOX-75,"A,B,E,F",7ORB_2;7ORB_3,2.5,Crystal structure of the L452R mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-75 and COVOX-253 Fabs,2021-07-07,10.1016/j.cell.2021.06.020
7P40,Antibody,P5C3,,7P40_1;7P40_2;7P40_3,3.5,P5C3 is a potent fab neutralizer,2021-10-13,10.1016/j.celrep.2021.109814
7PHG,Antibody,P5C3,,7PHG_1,4.3,MaP OF P5C3RBD Interface,2021-10-13,10.1016/j.celrep.2021.109814
7R6W,Antibody,S2X35,"H,L",7R6W_2,1.83,SARS-CoV-2 spike receptor-binding domain (RBD) in complex with S2X35 Fab and S309 Fab,2021-07-21,10.1038/s41586-021-03807-6
7R6W,Antibody,S309,"A,B",7R6W_1,1.83,SARS-CoV-2 spike receptor-binding domain (RBD) in complex with S2X35 Fab and S309 Fab,2021-07-21,10.1038/s41586-021-03807-6
7R6X,Antibody,S2E12,"C,D",7R6X_3,2.95,"SARS-CoV-2 spike receptor-binding domain (RBD) in complex with S2E12 Fab, S309 Fab, and S304 Fab",2021-07-21,10.1038/s41586-021-03807-6
7R6X,Antibody,S304,"H,L",7R6X_2,2.95,"SARS-CoV-2 spike receptor-binding domain (RBD) in complex with S2E12 Fab, S309 Fab, and S304 Fab",2021-07-21,10.1038/s41586-021-03807-6
7R6X,Antibody,S309,"A,B",7R6X_1,2.95,"SARS-CoV-2 spike receptor-binding domain (RBD) in complex with S2E12 Fab, S309 Fab, and S304 Fab",2021-07-21,10.1038/s41586-021-03807-6
7R7N,Antibody,S2D106,,7R7N_1,3.95,SARS-CoV-2 spike in complex with the S2D106 neutralizing antibody Fab fragment (local refinement of the RBD and S2D106),2021-07-21,10.1038/s41586-021-03807-6
7R8L,Antibody,C099,"H,L",7R8L_2,2.6,Structure of the SARS-CoV-2 RBD in complex with neutralizing antibody C099 and CR3022,2021-08-04,10.1016/j.immuni.2021.07.008
7R8L,Antibody,CR3022,"C,D",7R8L_1,2.6,Structure of the SARS-CoV-2 RBD in complex with neutralizing antibody C099 and CR3022,2021-08-04,10.1016/j.immuni.2021.07.008
7R8M,Antibody,C032,,7R8M_1;7R8M_2,3.4,Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C032,2021-08-04,10.1016/j.immuni.2021.07.008
7R8N,Antibody,C051,,7R8N_1;7R8N_2;7R8N_3,3.55,Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C051,2021-08-04,10.1016/j.immuni.2021.07.008
7R8O,Antibody,C548,,7R8O_1;7R8O_2;7R8O_3,3.5,Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C548,2021-08-04,10.1016/j.immuni.2021.07.008
7RA8,Antibody,S2X259,,7RA8_1;7RA8_2;7RA8_3,3.1,SARS-CoV-2 S glycoprotein in complex with S2X259 Fab,2021-08-04,10.1038/s41586-021-03817-4
7RAL,Antibody,S2X259,,7RAL_1,,SARS-CoV-2 S bound to S2X259 Fab (local refinement of the RBD/S2X259 variable domains),2021-08-04,10.1038/s41586-021-03817-4
7RKU,Antibody,C022,,,3.2,"Structure of the SARS-CoV-2 receptor binding domain in complex with the human neutralizing antibody Fab fragment, C022",2021-09-22,10.1016/j.celrep.2021.109760
7RKV,Antibody,C118,,7RKV_1;7RKV_2;7RKV_3,3.45,Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C118 (State 1),2021-09-22,10.1016/j.celrep.2021.109760
7RNJ,Antibody,S2P6,,,2.67,S2P6 Fab fragment bound to the SARS-CoV/SARS-CoV-2 spike stem helix peptide,2021-08-11,10.1126/science.abj3321
7RR0,Antibody,PDI 222,,7RR0_1,3.12,SARS-CoV-2 receptor binding domain bound to Fab PDI 222,2021-10-06,10.1016/j.celrep.2021.109822
7RW2,Antibody,5-7,,7RW2_1;7RW2_2;7RW2_3,3.5,Cryo-EM structure of NTD-directed neutralizing antibody 5-7 in complex with prefusion SARS-CoV-2 spike glycoprotein,2021-09-01,10.1101/2021.06.29.450397
7S0B,Antibody,N-612-056,,7S0B_1;7S0B_2,2.9,Structure of the SARS-CoV-2 RBD in complex with neutralizing antibody N-612-056,2021-10-06,10.1101/2021.09.14.460356
7S0C,Antibody,N-612-017,,7S0C_1;7S0C_2,3.25,Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody N-612-017,2021-10-06,10.1101/2021.09.14.460356
7S0D,Antibody,N-612-014,,7S0D_1;7S0D_2;7S0D_3,3.5,Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody N-612-014,2021-10-06,10.1101/2021.09.14.460356
7S0E,Antibody,N-612-004,,7S0E_1,4.9,Structure of the SARS-CoV-2 S1 subunit in complex with antibody N-612-004,2021-10-06,10.1101/2021.09.14.460356
7S3N,Antibody,Fab22,,,1.9,SARS-CoV-2 S stem helix peptide bound to Fab22,2021-10-27,10.1016/j.celrep.2021.109929
7S4S,Antibody,CoV11,,7S4S_1,2.05,Crystal Structure of SARS-CoV-2 S receptor-binding domain (RBD) in complex CoV11 Fab,2021-09-22,
7SO9,Antibody,S2L20,"B,C,I,J,N,O",7SO9_2;7SO9_3;7SO9_5,2.4,SARS-CoV-2 S B.1.617.2 delta variant + S2M11 + S2L20 Global Refinement,2021-11-17,10.1126/science.abl8506
7SO9,Antibody,S2M11,"D,E,G,H,L,M",7SO9_1;7SO9_4;7SO9_6,2.4,SARS-CoV-2 S B.1.617.2 delta variant + S2M11 + S2L20 Global Refinement,2021-11-17,10.1126/science.abl8506
7SOA,Antibody,S2L20,,7SOA_1,3.1,SARS-CoV-2 S NTD B.1.617.2 delta variant + S2L20 Local Refinement,2021-11-17,10.1126/science.abl8506
7SOB,Antibody,S2L20,"B,C,E,F,L,M",7SOB_2;7SOB_4;7SOB_5,2.4,SARS-CoV-2 S B.1.617.1 kappa variant + S309 + S2L20 Global Refinement,2021-11-17,10.1126/science.abl8506
7SOB,Antibody,S309,"G,H,I,J,N,O",7SOB_1;7SOB_3;7SOB_6,2.4,SARS-CoV-2 S B.1.617.1 kappa variant + S309 + S2L20 Global Refinement,2021-11-17,10.1126/science.abl8506
7SOC,Antibody,S309,,7SOC_1,3.3,SARS-CoV-2 S RBD B.1.617.1 kappa variant S309 Local Refinement,2021-11-17,10.1126/science.abl8506
7SOD,Antibody,S2L20,,7SOD_1,3.2,SARS-CoV-2 S NTD B.1.617.1 kappa variant S2L20 Local Refinement,2021-11-17,10.1126/science.abl8506
7SOE,Antibody,S2X303,,,2.8,SARS-CoV-2 S B.1.617.1 kappa variant + S2X303 Global Refinement,2021-11-17,10.1126/science.abl8506
7SOF,Antibody,S2X303,,,3.6,SARS-CoV-2 S NTD B.1.617.1 kappa variant S2X303 Local Refinement,2021-11-17,10.1126/science.abl8506
7V26,Antibody,XG005,,7V26_1;7V26_2;7V26_3,3.85,XG005-bound SARS-CoV-2 S,2021-10-20,10.1007/s13238-021-00871-6
7V2A,Antibody,XG014,,7V2A_1;7V2A_2;7V2A_3,"3.4, 3.4",SARS-CoV-2 Spike trimer in complex with XG014 Fab,2021-10-20,10.1007/s13238-021-00871-6
7VMU,Antibody,E4,,7VMU_1,2.89,Crystal Structure of SARS-CoV Spike Receptor-Binding Domain Complexed with Neutralizing Antibody,2021-11-03,
